US FDA grants fast track status to Wockhardt's novel antibiotic WCK 6777

Q: How long will it take to read this news story?

The story "US FDA grants fast track status to Wockhardt&#039;s novel antibiotic WCK 6777" has 422 words across 16 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "US FDA grants fast track status to Wockhardt&#039;s novel antibiotic WCK 6777" was covered 10 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 321 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #22920804</li><li>URL: https://beamstart.com/news/us-fda-grants-fast-track-17282941312444</li></ul>

Business Standard Logo Business Standard 10h ago

US FDA grants fast track status to Wockhardt's novel antibiotic WCK 6777 - Business Standard

Quick Summary:

The promising safety data from this study paves the way for the advancement of WCK 6777.

Earlier this month, the pharma company announced that one of its investigational drugs, Zaynich, had successfully treated critically ill patients with drug-resistant meningitis.

The study was conducted by the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in the United States.